title: [Adoptive immunotherapy: evaluation and perspectives in the treatment of certain cancers].
abstract: BACKGROUND
  Adoptive immunotherapy was first introduced in the 1980s. This new anticancer therapeutic approach has already demonstrated promising results in both animal models and humans affected by various tumors.
  
  
  BACKGROUND
  This review summarizes the requirements of such therapies involving either activated lymphocytes, tumor-infiltrating lymphocytes or activated macrophages. It focuses more particularly on the promising approaches that represent antigen presenting cells such as macrophages and antigen-loaded dendritic cells in the development of safe and effective cancer vaccines.
  
  
  CONCLUSIONS
  Standardized procedures for macrophages and dendritic cell generation, as well as preliminary results of clinical applications in patients with either prostate cancer or melanoma, are also discussed.
authors.affiliation: IDM Immuno-Designed Molecules, 172, Paris, France.
authors.forename: J
authors.initials: J
authors.lastname: Bartholeyns
authors.forename: V
authors.initials: V
authors.lastname: Bardot
authors.forename: M
authors.initials: M
authors.lastname: Chokri
authors.forename: J L
authors.initials: JL
authors.lastname: Romet-Lemonne
mesh_terms: D000818:Animals; D003713:Dendritic Cells / Q000276:immunology; D004195:Disease Models, Animal; D005544:Forecasting; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods* / Q000639:trends; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D008264:Macrophages / Q000276:immunology; D008297:Male; D008545:Melanoma / Q000628:therapy; D009369:Neoplasms / Q000628:therapy*; D011471:Prostatic Neoplasms / Q000628:therapy; D016896:Treatment Outcome